Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - Tamir Biotechnology, Inc. | alfacell_8k-030410.htm |
| EX-10.3 - AMENDMENT TO INVESTOR RIGHTS AGREEMENT - Tamir Biotechnology, Inc. | ex10-3.htm |
| EX-10.2 - AMENDMENT TO EACH 5% SENIOR SECURED CONVERTIBLE PROMISSORY NOTE - Tamir Biotechnology, Inc. | ex10-2.htm |
Exhibit 10.1
ALFACELL
CORPORATION
AMENDMENT
TO
SECURITIES PURCHASE AGREEMENT
February
26, 2010
This Amendment (this “Amendment”) to that
certain Securities Purchase Agreement dated as of October 19, 2009 (the “Agreement”) by and
among Alfacell Corporation, a Delaware corporation (the “Company”) and the
investors identified on the signature pages thereto (the “Purchasers”). Capitalized
terms used but not defined herein shall have the meanings ascribed to them in
the Agreement.
RECITALS
Whereas,
the Company and the Purchasers wish to amend the Agreement to extend the
deadline for which the Company shall seek stockholder approval for the
Certificate of Amendment until April 1, 2010 in accordance with Section 10(g) of
the Agreement.
AGREEMENT
Now,
Therefore, in consideration of the foregoing, and the representations,
warranties, covenants and conditions set forth below, the Company and the
Purchasers, intending to be legally bound, hereby agree as follows:
|
I.
|
AMENDMENT
TO THE AGREEMENT.
|
Section 5(c) of the Agreement is hereby
amended to read in its entirety as follows:
“(c). Reservation of
Shares. The Company shall reserve out of its authorized and
unissued Common Stock a number of shares of Common Stock equal to the numbers of
shares issuable upon conversion of the Notes and exercise of the Warrants (the
“Required
Reserve Amount”) for issuance upon any such conversion or
exercise. If at any time while the Notes or Warrants remain
outstanding the Company does not have a sufficient number of authorized and
unreserved shares of Common Stock to satisfy its obligation to reserve the
Required Reserve Amount, then the Company shall use its best efforts to increase
the Company’s authorized shares of Common Stock to an amount sufficient to allow
the Company to reserve the Required Reserve Amount for the Notes and Warrants
then outstanding. It is acknowledged by each Purchaser that (i) the
Company will not have a sufficient number of authorized and unreserved shares of
Common Stock to satisfy its obligation to reserve the Required Reserve Amount as
of the Closing Date and (ii) the Company will be required to obtain a vote of
its stockholders holding a majority of its outstanding Common Stock to approve
an amendment to its certificate of incorporation (the “Certificate of
Amendment”) to increase its authorized Common Stock. It is
understood and agreed that the Company will seek, through the distribution of
proxies, stockholder approval of the Certificate of Amendment on or prior to
April 1, 2010. It is hereby agreed to by each Purchaser that in
connection with such stockholder approval, each such Purchaser shall (i) take
all reasonable actions and use its best efforts to cause the Company to hold a
meeting of its stockholders to approve the Certificate of Amendment, including
causing the Purchaser’s Board Designee (as defined below), as applicable, to
recommend that the Company’s stockholders approve the Certificate of Amendment
and (ii) cause all shares owned by such Purchaser, including shares owned by
such Purchaser’s affiliates, representatives and family members, to be voted in
favor of the Certificate of Amendment.”
|
II.
|
GENERAL.
|
A. Except
as effected by this Amendment, the terms and provisions of the Agreement shall
remain unchanged and in full force and effect.
B. This
Amendment may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same
instrument.
C. This
Amendment shall be governed by and construed under the laws of the State of New
York as applied to agreements among New York residents, made and to be performed
entirely within the State of New York, without giving effect to conflicts of
laws principles.
D. The
titles and subtitles used in this Amendment are used for convenience only and
are not to be considered in construing or interpreting this
Amendment.
[SIGNATURE
PAGES FOLLOW]
The
parties have executed this Amendment as of the date first written
above.
|
ALFACELL
CORPORATION
By: /s/ Charles Muniz
Name:
Charles Muniz
Title:
President, Chief Executive Officer and Chief Financial
Officer
|
The
parties have executed this Amendment as of the date first written
above
|
PURCHASERS:
|
|
|
/s/ Charles
Muniz
|
___________________________________
|
|
Charles
Muniz
|
Colleen
A. Lowe
|
|
EUROPA
INTERNATIONAL, INC.
|
___________________________________
|
|
Corinne
M. Poquette
|
|
|
By: /s/ Fred Knoll
Name:
Fred Knoll
Title:
Knoll Capital Management, Investment
Manager
for Europa International, Inc.
|
___________________________________
David
J. McCash
|
|
UNILAB
LP
|
|
|
By:____________________________________
Name:
F. Patrick Ostronic
Title:
Director, Unilab GP Inc., General Partner for Unilab LP
|
|
|
MARY
M. MCCASH TRUST DECLARATION DECLARED OCTOBER 20, 2008
|
|
|
By:____________________________________
Name:
Mary M. McCash
Title:
Trustee
|
|
|
THE
MICHAEL J. MCCASH LIVING TRUST
|
|
|
By:____________________________________
Name:
Michael J. McCash
Title:
Trustee and Grantor
|